Skip to search formSkip to main contentSkip to account menu

Ibrolipim

A lipoprotein lipase (LPL) activator with antihyperlipidemic activity. Activation of LDL by ibrolipim lowers plasma triglycerides, with a concomitant… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Aim To observe the effect of ibrolipim on the expresstion of endothelin-1(ET-1) and von Willebrand factor(vWF) in cultured human… 
2012
2012
Two novel Ibrolipim analogs,diethyl 4-[2-(4-chloro-2-nitrophenyl)hydrazinecarbonyl]benzylphosphonate(5) with 28.1% total yield… 
2010
2010
AIM To observe the effect of ibrolipim on the apoptosis and protein kinase B(PKB) phasphorylation in cultured human umbilical… 
2009
2009
SUMMARY This study evaluates the induction potency of new drug candidates on mRNA levels of CYP1A2 and CYP3A4 in primary cultures… 
2008
2008
AIM To observe the change of protein kinase-B (Akt2) expression in myocardium of diabetic minipigs induced by high-fat/high… 
2007
2007
Objective: To evaluate whether ibrolipim(NO-1886),a lipoprotein lipase(LPL) activator,improves the postprandial lipid metabolism… 
2006
2006
The mRNA levels of human cytochrome P450 (CYP)2Cs and CYP3As in primary cultures of freshly isolated human hepatocytes were… 
2005
2005
AIM: To explore the application mechanism of NO-1886 (ibrolipim), a synthetic compound, improving dyslipidemia and inhibiting…